natgillin/translations-raw huggingface dataset:
patients having “haemo-dialysis”- where a “dialysis” machine removes waste products from the blood patients who are going to have “haemo-dialysis” in the future.
patsientidel, kes saavad „hemodialüüsi“ – kus „dialüüsi“ masin eemaldab verest jääkaineid patsientidel, kes hakkavad saama edaspidi “hemodialüüsi”.
Patients HBV DNA undetectable by PCR
PCR järgi mittemääratava HBV DNA tasemega patsientide
Patients homozygous for the UGT1A1*28 allele were given a lower initial dose of ONIVYDE (see section 4.2).
UGT1A1*28 alleeli suhtes homosügootsetele patsientidele manustati väiksem ONIVYDE algannus (vt lõik 4.2).
Patients hypersensitive to Insulin Human Winthrop Basal for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Insulin Human Winthrop Basal’ile ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insulin Human Winthrop Basal for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Preparaadile Insulin Human Winthrop Basal ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib Insulin Human Winthrop Basal’i manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insulin Human Winthrop Comb 15 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Insulin Human Winthrop Comb 15-le ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib preparaadi Insulin Human Winthrop Comb 15 manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insulin Human Winthrop Comb 15 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Preparaadile Insulin Human Winthrop Comb 15 ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib Insulin Human Winthrop Comb 15 manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insulin Human Winthrop Comb 25 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Insulin Human Winthrop Comb 25-le ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib preparaadi Insulin Human Winthrop Comb 25 manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insulin Human Winthrop Comb 25 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Preparaadile Insulin Human Winthrop Comb 25 ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib Insulin Human Winthrop Comb 25 manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insulin Human Winthrop Comb 30 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Insulin Human Winthrop Comb 30-le ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib preparaadi Insulin Human Winthrop Comb 30 manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insulin Human Winthrop Comb 30 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Preparaadile Insulin Human Winthrop Comb 30 ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib Insulin Human Winthrop Comb 30 manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insulin Human Winthrop Comb 50 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Insulin Human Winthrop Comb 50-le ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib preparaadi Insulin Human Winthrop Comb 50 manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insulin Human Winthrop Comb 50 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Preparaadile Insulin Human Winthrop Comb 50 ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib Insulin Human Winthrop Comb 50 manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insulin Human Winthrop Infusat for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Preparaadile Insulin Human Winthrop Infusat ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib Insulin Human Winthrop Infusat’i manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insulin Human Winthrop Rapid for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Insulin Human Winthrop Rapid’ile ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insulin Human Winthrop Rapid for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Preparaadile Insulin Human Winthrop Rapid ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib Insulin Human Winthrop Rapid’i manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insuman Basal for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Insuman Basal’ile ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insuman Basal for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Preparaadile Insuman Basal ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib Insuman Basal’i manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insuman Comb 15 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Insuman Comb 15-le ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib preparaadi Insuman Comb 15 manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insuman Comb 15 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Preparaadile Insuman Comb 15 ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib Insuman Comb 15 manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insuman Comb 25 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Insuman Comb 25-le ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib preparaadi Insuman Comb 25 manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insuman Comb 25 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Preparaadile Insuman Comb 25 ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib Insuman Comb 25 manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insuman Comb 30 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Insuman Comb 30-le ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib preparaadi Insuman Comb 30 manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insuman Comb 30 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Preparaadile Insuman Comb 30 ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib Insuman Comb 30 manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insuman Comb 50 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Insuman Comb 50-le ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib preparaadi Insuman Comb 50 manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insuman Comb 50 for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Preparaadile Insuman Comb 50 ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib Insuman Comb 50 manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insuman Implantable for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – if necessary – in conjunction with anti-allergic treatment.
Insuman Implantable suhtes ülitundlikud patsiendid, kelle jaoks puudub alternatiivne insuliinpreparaat, tohivad ravi jätkata ainult hoolika meditsiinilise järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insuman Infusat for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Preparaadile Insuman Infusat ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib Insuman Infusat’i manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insuman Rapid for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Insuman Rapid’ile ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients hypersensitive to Insuman Rapid for whom no better tolerated preparation is available must only continue treatment under close medical supervision and – where necessary – in conjunction with anti-allergic treatment.
Preparaadile Insuman Rapid ülitundlikele inimestele, kelle jaoks puudub alternatiivne insuliinpreparaat, tohib Insuman Rapid’i manustamist jätkata ainult hoolika järelevalve all ning vajadusel samaaegset allergiavastast ravi rakendades.
Patients in a clinical trial for type 2 diabetes, who used a regimen of EXUBERA in combination with long- or intermediate-acting insulin, had similar changes in HbA1c compared with patients treated with subcutaneous insulin alone.
2. tüüpi diabeedi kliinilistes uuringutes esines patsientidel, kes kasutasid EXUBERAt kombinatsioonis pika või keskmise toimeajaga insuliiniga, samasugused HbA1c muutused kui patsientidel, keda raviti ainult subkutaanse insuliiniga.
Patients in a severely immunocompromised state
Tugevalt immuunkomprimeeritud patsiendid.
Patients in aHUS C10-003 received Soliris for a minimum of 26 weeks.
aHUS-i uuringus C10-003 manustati patsientidele Soliris’t vähemalt 26 nädalat.
Patients in aHUS Study C08-002 A/B received Soliris for a minimum of 26 weeks.
Uuringus C08-002A/B manustati aHUS’iga patsientidele Soliris’t minimaalselt 26 nädala jooksul.
Patients in aHUS study C08-003A/B received Soliris for a minimum of 26 weeks.
Uuringus C08-003A/B manustati aHUS’iga patsientidele Soliris’t minimaalselt 26 nädala jooksul.
Patients in aHUS Study C10-004 received Soliris for a minimum of 26 weeks.
aHUS-i uuringus C10-004 manustati patsientidele Soliris’t vähemalt 26 nädalat.
Patients in all treatment groups typically received between 2 and 4 antihypertensive agents (e.g., diuretics, beta blockers, alpha blockers) to reach a predefined blood pressure goal of ≤ 135/85 mmHg or a 10 mmHg reduction in systolic pressure if baseline was > 160 mmHg.
Kõikide ravigruppide patsiendid said tüüpiliselt 2 kuni 4 antihüpertensiivset ravimit (nt diureetikumi, beeta- adrenoblokaatorit, alfa-adrenoblokaaatorit), et saavutada ettenähtud vererõhu väärtus ≤ 135/85 mmHg või 10 mmHg süstoolse rõhu langus, kui algväärtus oli > 160 mmHg.
Patients in all treatment groups typically received between 2 and 4 antihypertensive agents (e.g., diuretics, beta blockers, alpha blockers) to reach a predefined blood pressure goal of ≤ 135/85 mmHg or a 10 mmHg reduction in systolic pressure if baseline was > 160 mmHg.
Kõikide ravigruppide patsiendid said tüüpiliselt 2 kuni 4 antihüpertensiivset ravimit (nt diureetikumi, beetaadrenoblokaatorit, alfa-adrenoblokaaatorit), et saavutada ettenähtud vererõhu väärtus ≤ 135/85 mmHg või 10 mmHg süstoolse rõhu langus, kui algväärtus oli > 160 mmHg.
Patients in all treatment groups typically received between 2 and 4 antihypertensive agents (e.g., diuretics, beta blockers, alpha blockers) to reach a predefined blood pressure goal of ≤ 135/85 mmHg or a 10 mmHg reduction in systolic pressure if baseline was > 160 mmHg.
Kõikide ravigruppide patsiendid said üldjuhul 2 kuni 4 antihüpertensiivset ravimit (nt diureetikumi, beeta- adrenoblokaatorit, alfa-adrenoblokaaatorit), et saavutada ettenähtud vererõhu väärtus ≤ 135/85 mmHg või 10 mmHg süstoolse rõhu langus, kui algväärtus oli > 160 mmHg.
Patients in all treatment groups typically received between 2 and 4 antihypertensive agents (e.g., diuretics, beta blockers, alpha blockers) to reach a predefined blood pressure goal of ≤ 135/85 mmHg or a 10 mmHg reduction in systolic pressure if baseline was > 160 mmHg.
Kõikide ravigruppide patsiendid said üldjuhul 2 kuni 4 antihüpertensiivset ravimit (nt diureetikumi, beeta-adrenoblokaatorit, alfa-adrenoblokaaatorit), et saavutada ettenähtud vererõhu väärtus ≤ 135/85 mmHg või 10 mmHg süstoolse rõhu langus, kui algväärtus oli > 160 mmHg.
Patients in an autologous blood predonation programme
Autoloogse vere kogumise (predonatsiooni) korral
Patients in an autologous blood predonation programme have been reported to show a slightly higher frequency of thromboembolic events.
Patsientidel, kellel viiakse läbi autoloogse vere kogumist, on veidi suurenenud trombemboolsete seisundite esinemissagedus.
Patients in both arms received 1000mg of pulse intravenous (IV) methylprednisolone (or another equivalent-dose glucocorticoid) per day for 1 to 3 days, followed by oral prednisone (1 mg/kg/day, not exceeding 80 mg/day).
Mõlema grupi patsiendid said intravenoosset (i.v.) pulssravi metüülprednisolooniga annuses 1000 mg ööpäevas (või mõnda teist ekvivalentses annuses glükokortikoidi) 1...3 päeva jooksul, millele järgnes suukaudse prednisolooni manustamine (1 mg/kg/päevas, mitte üle 80 mg ööpäevas).
Patients in both prospective studies were treated with Soliris for 26 weeks and most patients enrolled into a long-term, open-label extension study.
Mõlemas prospektiivses uuringus raviti patsiente Soliris’ega 26 nädala vältel ning enamik patsiente kaasati pikaajalisse avatud jätku-uuringusse.
Patients in both studies had plaque psoriasis (Body Surface Area [BSA] ≥10% and Psoriasis Area and Severity Index [PASI] score ≥12).
Mõlemas uuringus osalenud patsientidel esines naastuline psoriaas (Kehapinna [BSA] ≥ 10% ja psoriaasipinna ning raskusastme indeksi [PASI] skoor ≥ 12).
Patients in both study arms were permitted to switch to oral fluconazole after at least 10 days of intravenous therapy, provided that they were able to tolerate oral medication and were afebrile for at least 24 hours, and that the most recent blood cultures were negative for Candida species.
Mõlemas uuringugrupis lubati patsientidel pärast vähemalt 10 päeva kestnud intravenoosset ravi üle minna flukonasooli suukaudsele manustamisele (juhul kui nad talusid suukaudset ravi), olid olnud palavikuta vähemalt 24 tundi ja nende viimased verekülvid olid olnud Candida suhtes negatiivsed.
Patients in both treatment arms were to receive 7 weeks of CRT following induction chemotherapy with a minimum interval of 3 weeks and no later than 8 weeks after start of the last cycle (day 22 to day 56 of last cycle).
Minimaalselt 3 nädalat ja maksimaalselt 8 nädalat pärast induktsioonkemoteraapia viimase tsükli algust (viimase tsükli 22. päev kuni 56. päev) pidid mõlema ravirühma patsiendid saama 7 nädalat KRT-d.
Patients in clinical response (decrease in CDAI ≥ 70) at Week 4 were stratified and analysed separately from those not in clinical response at Week 4.
Patsiendid, kes said kliinilise vastuse (vähenemine CDAI ≥ 70) 4. nädalal stratifitseeriti ja analüüsiti eraldi nendest, kellel 4. nädalaks kliinilist vastust ei olnud.
Patients in clinical response (decrease in CDAI ≥ 70) at week 4 were stratified and analysed separately from those not in clinical response at week 4.
Patsiendid, kes said kliinilise vastuse (vähenemine CDAI  70) 4. nädalal stratifitseeriti ja analüüsiti eraldi nendest, kellel 4. nädalaks ei olnud kliinilist vastust.
Patients in controlled clinical trials in MS had serum samples collected 1, 3, and 12 months after each treatment course for determination of anti-alemtuzumab antibodies.
Hulgiskleroosi kontrollitud kliinilistes uuringutes osalevatelt patsientidelt koguti 1., 3. ja 12. kuul pärast iga ravikuuri algust seerumiproovid, et määrata alemtuzumabivastaseid antikehi.
Patients in each treatment group were maintained at their optimal dose for 6 months.
Igas ravigrupis säilitati patsientidel nende optimaalne annus 6 kuu jooksul.
Patients in each treatment group were maintained at their optimal dose for 6 months.
Kõikide ravigruppide patsiente raviti optimaalsete annustega 6 kuud.
Patients in part II (double-blind) received either Ilaris 4 mg/kg or placebo every 4 weeks until 37 flare events occurred.
Teises osas (topeltpime) patsiendid said kas Ilaris’t 4 mg/kg või platseebot iga 4 nädala järel kuni esines 37 ägenemise juhtumit.
Patients in PIX 301 were required to have been sensitive to prior anthracycline therapy (confirmed or unconfirmed CR or PR).
Uuringu PIX 301 patsiendid pidid olema tundlikud eelnenud antratsükliinravile (kinnitatud või kinnitamata täielik ravivastus (CR) või osaline ravivastus (PR)).
Patients in response were followed for an additional 24 weeks off- treatment.
Kriteeriumidele vastavaid patsiente jälgiti ravijärgselt lisaks 24 nädalat.
Patients in rheumatoid arthritis studies I, II and III were tested at multiple time points for anti- adalimumab antibodies during the 6 to 12 month period.
Reumatoidartriidi uuringutes I, II ja III osalenud patsiente uuriti 6...12-kuulise perioodi jooksul mitmel ajahetkel adalimumabivastaste antikehade suhtes.
Patients in studies I – V had a mean Disease Activity Score (DAS28) of 6.5–6.8 at baseline.
Uuringutes I-V osalenud patsientidel oli haiguse aktiivsuse skoor (DAS28) uuringueelselt 6,5...6,8.
Patients in studies I – V had a mean Disease Activity Score (DAS28) of 6.5–6.8 at baseline.
Uuringutes I...V osalenud patsientidel oli haiguse aktiivsuse skoor (Disease Activity Score, DAS28) uuringueelselt 6,5...6,8.
Patients in studies MCL-002 and MCL-001 that experienced Grade 1 and 2 TFR were treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms.
Uuringutes MCL-002 ja MCL-001 osalenud patsiente, kellel tekkis 1. ja 2. astme kasvaja ägenemisreaktsioon, raviti kortikosteroidide, mittesteroidsete põletikuvastaste ravimite ja/või narkootiliste analgeetikumidega kasvaja ägenemisreaktsiooni sümptomite leevendamiseks.
Patients in the Abraxane/carboplatin arm had a significantly higher overall response rate compared with patients in the control arm: 33% versus 25%, p = 0.005 (Table 12).
Abraxane’i/karboplatiini rühma patsientidel oli üldine ravivastuse määr oluliselt kõrgem, võrreldes kontrollrühma patsientidega: 33% versus 25%, p = 0,005 (tabel 12).
Patients in the adalimumab arm received an adalimumab SC injection (40 mg) q2w plus an IV placebo infusion q4w.
Adalimumabi rühma patsiendid said adalimumabi nahaaluse süstina (40 mg) iga 2 nädala järel pluss platseebot veeniinfusioonina iga 4 nädala järel.
Patients in the alirocumab 300 mg every 4 weeks treatment group received alternating placebo injections to maintain blinding in regard to injection frequency.
Alirokumabi 300 mg iga 4 nädala järel ravirühma patsientidele manustati vahelduvalt platseebosüste pimemeetodi säilitamiseks süstimissageduse osas.
Patients in the alirocumab 300 mg every 4 weeks treatment group received alternating placebo injections to maintain blinding in regard to injection frequency.
Patsiendid, kes olid rühmas, kus alrokumabi manustati 300 mg iga 4 nädala järel, said vahelduvalt platseebosüste, et säilitada pimemeetodit manustamissageduse osas.